AbbVie · Multi-Quarter Financial Trends

16 quarters · As reported by the company · Amounts in USD billions← ABBV

Quarter	Period End	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Net Margin	Free Cash Flow ($B)	EPS	Buybacks ($B)	Dividends ($B)
FY2026 Q2	2026-06-30	16.99	+10.2%	74.7%	6.43	3.61	21.3%	3.11	2.03	0.01	3.07
FY2026 Q1	2026-03-31	15.00	+12.4%	71.9%	3.99	0.70	4.6%	3.56	0.39	1.49	3.09
FY2025 Q4	2025-12-31	16.62	+10.0%	—	—	1.82	10.9%	4.89	1.02	0.00	2.91
FY2025 Q3	2025-09-30	15.78	+9.1%	66.4%	1.90	0.19	1.2%	6.64	0.10	0.00	2.91
FY2025 Q2	2025-06-30	15.42	+6.6%	71.8%	4.89	0.94	6.1%	4.88	0.52	0.01	2.91
FY2025 Q1	2025-03-31	13.34	+8.4%	70.0%	3.73	1.29	9.6%	1.40	0.72	0.96	2.93
FY2024 Q4	2024-12-31	15.10	+5.6%	—	—	-0.02	-0.1%	6.76	-0.02	0.36	2.75
FY2024 Q3	2024-09-30	14.46	+3.8%	70.9%	3.83	1.56	10.8%	5.20	0.88	0.02	2.75
FY2024 Q2	2024-06-30	14.46	+4.3%	70.9%	4.00	1.37	9.5%	2.03	0.77	0.01	2.75
FY2024 Q1	2024-03-31	12.31	+0.7%	66.7%	2.80	1.37	11.1%	3.85	0.77	1.32	2.77
FY2023 Q4	2023-12-31	14.30	−5.4%	—	—	0.82	5.7%	4.55	0.46	0.00	2.63
FY2023 Q3	2023-09-30	13.93	−6.0%	53.4%	2.28	1.78	12.8%	7.36	1.00	0.00	2.63
FY2023 Q2	2023-06-30	13.87	—	69.4%	4.51	2.02	14.6%	6.14	1.14	0.01	2.63
FY2023 Q1	2023-03-31	12.23	—	67.4%	2.77	0.24	2.0%	4.02	0.13	1.96	2.66
FY2022 Q4	2022-12-31	15.12	—	—	—	2.47	16.4%	7.22	1.38	0.00	2.51
FY2022 Q3	2022-09-30	14.81	—	66.1%	4.60	3.95	26.7%	7.43	2.21	0.00	2.50

Quarterly figures come from the company's 10-Q and 10-K filings. The fourth quarter is derived as the full year minus the first three quarters; cash flow items are converted from fiscal year-to-date totals into single quarters.